Pre-pandemic SARS-CoV-2 serological reactivity in rural malaria-experienced Cambodians

Greater Mekong inhabitants are exposed to pathogens, zoonotic and otherwise, that may influence SARS-CoV-2 seroreactivity. A pre-pandemic (2005 to 2011) serosurvey of from 528 malaria-experienced Cambodians demonstrated higher-than-expected (up to 13.8 %) positivity of non-neutralizing IgG to SARS-CoV-2 spike and RBD antigens. These findings have implications for interpreting large-scale serosurveys.

There are no published SARS-CoV-2 serosurveys in the Greater Mekong Subregion (GMS), 28 aside from screening healthcare workers in two urban hospital-based settings (1,2). These 29 antibody-based studies are necessary to estimate at-risk populations and to direct disease 30 containment measures; however, prior to informing public health decisions, serological assays 31 require careful country-specific calibration as several regions report fluctuating results or high 32 background reactivity in different populations (3)(4)(5). This variability may be attributable to the 33 myriad serological assays, the hypothesized cross-reactivity from 'common cold'-type 34 respiratory coronaviruses (6), prior Plasmodium infections (7-9), or previously uncharacterized 35 betacoronaviruses in wildlife populations found in the rural GMS (10-12). While countless 36 serological SARS-CoV-2 investigations are currently underway, it is prudent to consider how the 37 broad pathogen diversity in the GMS may influence estimations of SARS-CoV-2 seroprevalence.

38
The Study 39 We tested sera or plasma from 528 malaria-infected Cambodian individuals sampled from 2005 This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. SARS-CoV-2 shows varying levels of spike protein sequence homology, with the highest for 47 SARS-CoV-1 (76% identity; 87% similarity) and the lowest for the 'common cold' coronavirus 48 HKU1 (29% identity; 40% similarity)(13). Reactivity to both spike and RBD antigens above  Table 1).

55
To test whether the higher-than-expected positivity was an artifact of our in-house ELISA assay, 56 we assayed a subset of samples with a commercially validated SARS-CoV-2 Spike S1-RBD IgG 57 ELISA Detection commercial Kit (Genscript). Of the 24 individuals who were seronegative and 58 11 seropositives in the in-house assay, 18 tested negative and 9 tested positive in the commercial 59 test, respectively, yielding an overall concordance of 77.1% between assays (Appendix Table 2).

60
This inconsistency may be explained by the stringency of the in-house assay that tests both spike 61 and RBD versus the commercial kit that tests for RBD only; nevertheless, the higher-than-62 expected positivity is observed in both assays. Since common cold coronaviruses do circulate in 63 Cambodia, but no documented SARS-CoV-1 or MERS, we tested a subset of the cohort for IgG 64 for use under a CC0 license.
This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. CoV-2 serostatus (Figure 2A). 66 We further tested 289 subjects to assess if there was a relationship between antibodies to 67 Plasmodium spp. and SARS-CoV-2 proteins using two known malarial antigens, Plasmodium  Figure 2D). This finding corroborates recent observations that higher SARS-CoV-2 77 seroreactivity by ELISA or rapid tests is detected in individuals from malaria-endemic areas, 78 expanding previous observations to include Southeast Asia (7-9). We also evaluated the 79 samples for seroreactivity against the nucleocapsid (NC) protein that also positively correlated 80 with the AMA-1 IgG antibodies. Only NC antibodies were weakly correlated to Pfs25 81 antibodies, which reinforces the argument for non-specific reactivity of NC ( Figure 2E). Pre-82 incubation with 10 mg/ml of AMA-1 or BSA had no significant effect in the reactivity to SARS-83 CoV-2 Spike S1-RBD ( Figure 2F). Taken together with studies elsewhere, Plasmodium spp. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
The copyright holder for this this version posted September 28, 2021.  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. We found in a widely-used, highly specific, and validated enzyme linked-immunosorbent assay 109 that approximately 4 -14% of pre-pandemic Cambodian sera samples were positive for non-110 neutralizing antibodies to SARS-CoV-2 spike and RBD antigens using various standardized 111 optical density cut-off values (4,13,14). A relationship was noted between increased SARS-CoV-112 2 seroreactivity and anti-malarial humoral immunity as was also recently shown in Africa (7).

113
The plausibility of regular spillover events, or simply increased exposure to uncharacterized 114 betacoronaviruses, as a reason for SARS-CoV-2 cross-reactivity is also increased in these high-  This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.